Litcius/Paper detail

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence

Antonio Passaro, Albrecht Stenzinger, Solange Peters

2020Cancer Cell43 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabImmunotherapyBiomarkerCancer immunotherapyMedicineCancerCompanion diagnosticCancer researchOncologyInternal medicineBiologyGeneticsCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology Research
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence | Litcius